Skip to main content

Tobramycin, Serum, Peak

CPT 80200
Synonyms
  • AK-Tob™
  • Nebcin®
  • TOBI®
  • Tobrex®

Test Details

Methodology

Immunoassay

Result Turnaround Time

Within 1 day

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

Tobramycin is administered to treat serious infections caused by aerobic gram-negative bacilli (eg, a number of the Enterobacteriaceae, P aeruginosa). These include lower respiratory tract, intra-abdominal, soft tissue, bone or joint, wound, and complicated urinary tract infections; bacteremias; and meningitis.

Tobramycin frequently is the aminoglycoside of choice for infections caused by P aeruginosa because of its greater in vitro activity against this organism; however, superior clinical efficacy is unproven. It usually is given in combination with an antipseudomonal penicillin for severe, systemic P aeruginosa infections.

Some infectious disease experts have preferred the more costly tobramycin to gentamicin for general use in hospitals where resistance is not a problem because it appears to be less nephrotoxic; however, this does not appear to be warranted when all of the available data are evaluated. Amikacin is the aminoglycoside of choice in hospitals where gentamicin and tobramycin resistance is a problem.

Special Instructions

Peak levels should be ordered using Test No. 007154. Trough levels should be ordered using Test No. 007155. Please label tubes appropriately as "peak" and "trough."

References

AMA, Division of Drugs and Toxicology, Drug Evaluations Subscription, Chicago, IL: American Medical Association, Winter 1993.

Custom Additional Information

Tobramycin is cleared by the kidney, and accumulates in renal tubular cells. Nephrotoxicity is most closely related to the length of time that trough levels are >2 μg/mL. Creatinine levels should be monitored every two to three days as this serves as a useful indicator of impending renal toxicity. The initial toxic result is nonoliguric renal failure that is usually reversible if the drug is discontinued. Continued administration of tobramycin may produce oliguric renal failure. Nephrotoxicity may occur in as many as 10% to 25% of patients receiving aminoglycosides; most of this toxicity can be eliminated by monitoring levels and adjusting dosing schedules accordingly. Aminoglycosides may also cause irreversible ototoxicity that manifests itself clinically as hearing loss. Aminoglycoside ototoxicity is relatively uncommon and clinical trials where levels were carefully monitored and dosing adjusted failed to show a correlation between auditory toxicity and plasma aminoglycoside levels. In situations where dosing is not adjusted, however, sustained high levels may be associated with ototoxicity. This association is far from clear cut, and new once-daily dosing regimens (and associated high peak serum concentrations) that fail to enhance toxicity further complicate this issue.

Specimen Requirements

Specimen

Serum or plasma

Volume

1 mL

Minimum Volume

0.3 mL

Container

Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.

Collection Instructions

Transfer separated serum or plasma to a plastic transport tube. Both peak and trough concentrations should be monitored. The trough sample is drawn immediately prior to the next dose. Peak samples should be drawn 60 minutes after an I.M. injection, 30 minutes after the end of a 30-minute I.V. infusion or immediately after a 60-minute I.V. infusion.

Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

Reference Range

Therapeutic: peak: 6.0−10.0 μg/mL, trough: 0.5−1.5 μg/mL

Storage Instructions

Room temperature

Causes for Rejection

Gel-barrier tube; severe hemolysis; lipemia; icteric specimen

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
007154 Tobramycin Peak, Serum 007254 Tobramycin Peak, Serum ug/mL 4057-6
Order Code007154
Order Code NameTobramycin Peak, Serum
Order Loinc
Result Code007254
Result Code NameTobramycin Peak, Serum
UofMug/mL
Result LOINC4057-6